{"id":410008,"date":"2021-01-06T19:07:55","date_gmt":"2021-01-07T00:07:55","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410008"},"modified":"2021-01-06T19:07:55","modified_gmt":"2021-01-07T00:07:55","slug":"immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/","title":{"rendered":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC)<\/li>\n<li>Recruitment of additional 1<sup>st<\/sup> line non small cell lung cancer (NSCLC) patients started<\/li>\n<li>Further interim data from TACTI-002 expected in H1 2021<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Sydney, AUSTRALIA, Jan.  07, 2021  (GLOBE NEWSWIRE) &#8212;  Immutep Limited <\/strong>(ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study.<\/p>\n<p align=\"justify\">This completes recruitment for Part C of the trial which evaluates 2nd line HNSCC patients being treated with Immutep\u2019s lead product candidate, eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab).<\/p>\n<p align=\"justify\">Immutep reported encouraging interim data from TACTI-002 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting on 10 November 2020. The data from 2<sup>nd<\/sup> line HNSCC patients was very robust and forms an excellent basis for additional clinical development in this indication.<\/p>\n<p align=\"justify\">Also the recruitment of an additional 74 patients with 1<sup>st<\/sup> line NSCLC in accordance with the TACTI-002 collaboration trial expansion plans announced on November 19<sup>th<\/sup>, 2020, has commenced with now 4 patients newly recruited, adding to the 36 patients already enrolled prior to the expansion. In total 40 of 110 patients with 1st line NSCLC have now been recruited in Part A of TACTI-002.<\/p>\n<p align=\"justify\">The Company expects to report more data from TACTI-002 in the first half of CY 2021.<\/p>\n<p align=\"justify\">\n        <strong>About the TACTI-002 Trial<\/strong><br \/>\n        <br \/>TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck &amp; Co., Inc., Kenilworth, NJ, USA (known as \u201cMSD\u201d outside the United States and Canada). The study is evaluating the combination of efti with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.<\/p>\n<p align=\"justify\">More information about the trial can be found on Immutep\u2019s website or on ClinicalTrials.gov (Identifier:NCT03625323).<\/p>\n<p align=\"justify\">\n        <strong>About Immutep<\/strong><br \/>\n        <br \/>Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.<\/p>\n<p align=\"justify\">Immutep\u2019s current lead product candidate is eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep\u2019s large pharmaceutical partners.<\/p>\n<p align=\"justify\">Further information can be found on the Company\u2019s website <u>www.immutep.com<\/u> or by contacting:<\/p>\n<p align=\"justify\">\n        <strong>Australian Investors\/Media:<\/strong><br \/>\n        <br \/>Catherine Strong, Citadel-MAGNUS<br \/>+61 (0)406 759 268; <u>cstrong@citadelmagnus.com<\/u><\/p>\n<p align=\"justify\">\n        <strong>U.S. Media:<\/strong><br \/>\n        <br \/>Tim McCarthy, LifeSci Advisors<br \/>+1 (212) 915.2564;\u00a0<u>tim@lifesciadvisors.com<\/u><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/40388cef-d1e9-4e43-b438-49201d2705a6\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients started Further interim data from TACTI-002 expected in H1 2021 Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study. This completes recruitment for Part C of the trial which evaluates 2nd line HNSCC patients being treated with Immutep\u2019s lead product candidate, eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab). &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410008","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients started Further interim data from TACTI-002 expected in H1 2021 Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study. This completes recruitment for Part C of the trial which evaluates 2nd line HNSCC patients being treated with Immutep\u2019s lead product candidate, eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab). &hellip; Continue reading &quot;Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T00:07:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study\",\"datePublished\":\"2021-01-07T00:07:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/\"},\"wordCount\":501,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/\",\"name\":\"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=\",\"datePublished\":\"2021-01-07T00:07:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/","og_locale":"en_US","og_type":"article","og_title":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Market Newsdesk","og_description":"Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients started Further interim data from TACTI-002 expected in H1 2021 Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study. This completes recruitment for Part C of the trial which evaluates 2nd line HNSCC patients being treated with Immutep\u2019s lead product candidate, eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d) in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab). &hellip; Continue reading \"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T00:07:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study","datePublished":"2021-01-07T00:07:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/"},"wordCount":501,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/","name":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=","datePublished":"2021-01-07T00:07:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg4OSMzOTA4MTUyIzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410008"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410008\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}